@article{2bb7a940158311df803f000ea68e967b,
title = "Cost-effectiveness of varenicline for smoking cessation",
abstract = "Smoking cessation therapies are among the most cost-effective preventive healthcare measures. Varenicline is a relatively new drug developed especially for this purpose, and it has been shown to achieve better quit rates than nicotine replacement therapies and the non-nicotine-based drug, bupropion, which has been in use for some years. The cost-effectiveness of varenicline depends on the cost of the therapy and the cost-savings achieved through reduced morbidity and mortality; several investigations, based on the situation in different countries, indicate that varenicline either finances itself fully through the cost-savings achieved or offers additional life-years at a lower price than that paid elsewhere in the healthcare sector.",
author = "Hans Keiding",
year = "2009",
doi = "10.1586/erp.09.19",
language = "English",
volume = "9",
pages = "215--221",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Taylor & Francis",
number = "3",
}